Skip to main content
Erschienen in:

19.04.2023 | Original Paper

Elevated expression of endocan in the development of cervical squamous neoplasia of the uterus

verfasst von: Midori Sato, Ayano Inoue, Akira Takasawa, Kumi Takasawa, Daisuke Kyuno, Yusuke Ono, Kazufumi Magara, Makoto Osanai

Erschienen in: Medical Molecular Morphology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Accumulated evidence has shown that endocan, which was originally called endothelial cell-specific molecule-1, is an attractive prognostic factor in a variety of cancers. However, the relevance of endocan expression in human malignancies remains to be clarified. In the present study, the expression of endocan in cervical squamous neoplasia of the uterus, including low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), as well as in invasive squamous cell carcinoma was examined by immunohistochemistry. Endocan was not sufficiently expressed in the normal cervical epithelium. Endocan expression was present in LSIL cases but was limited to basal and parabasal areas of the cells. HSIL cases exhibited strong expression of endocan with widely distributed expression toward the epithelial surface. In contrast, further strong expression of endocan was not observed in patients with invasive carcinoma. This study is the first study showing increased expression of endocan in precancerous dysplastic lesions and malignancy of the cervix. The data suggest that a high expression level of endocan potentially contributes to the development of cervical squamous neoplasia of the uterus.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458–20464CrossRefPubMed Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458–20464CrossRefPubMed
2.
Zurück zum Zitat Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y (2012) Expression and distribution of endocan in human tissues. Biotech Histochem 87:172–178CrossRefPubMed Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y (2012) Expression and distribution of endocan in human tissues. Biotech Histochem 87:172–178CrossRefPubMed
3.
Zurück zum Zitat Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37PubMed Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37PubMed
4.
Zurück zum Zitat Öztop N, Özer PK, Demir S, Beyaz S, Tiryaki TO, Özkan G, Aydogan M, Bugra MZZ, Çolakoglu B, Büyüköztürkn S, Nalçacı M, Yavuz AS, Gelincik A (2021) Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastocytosis. Ann Allergy Asthma Immunol 127:76–82CrossRefPubMed Öztop N, Özer PK, Demir S, Beyaz S, Tiryaki TO, Özkan G, Aydogan M, Bugra MZZ, Çolakoglu B, Büyüköztürkn S, Nalçacı M, Yavuz AS, Gelincik A (2021) Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastocytosis. Ann Allergy Asthma Immunol 127:76–82CrossRefPubMed
5.
Zurück zum Zitat Rocha SF, Schiller M, Jing D, Li H, Butz S, Vestweber D, Biljes D, Drexler HCA, Nieminen-Kelhä M, Vajkoczy P, Adams S, Benedito R, Adams RH (2014) sm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res 115:581–590CrossRefPubMed Rocha SF, Schiller M, Jing D, Li H, Butz S, Vestweber D, Biljes D, Drexler HCA, Nieminen-Kelhä M, Vajkoczy P, Adams S, Benedito R, Adams RH (2014) sm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res 115:581–590CrossRefPubMed
6.
Zurück zum Zitat Lu J, Liu Q, Zhu L, Liu Y, Zhu X, Peng S, Chen M, Li P (2022) Endothelial cell-specific molecule 1 drives cervical cancer progression. Cell Death Dis 13:1043CrossRefPubMedPubMedCentral Lu J, Liu Q, Zhu L, Liu Y, Zhu X, Peng S, Chen M, Li P (2022) Endothelial cell-specific molecule 1 drives cervical cancer progression. Cell Death Dis 13:1043CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Yang J, Yang Q, Yu S, Zhang X (2005) Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep 3:279–283CrossRef Yang J, Yang Q, Yu S, Zhang X (2005) Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep 3:279–283CrossRef
8.
Zurück zum Zitat Cui Y, Guo W, Li Y, Shi J, Ma S, Guan F (2021) Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer. Esophagus 18:326–338CrossRefPubMed Cui Y, Guo W, Li Y, Shi J, Ma S, Guan F (2021) Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer. Esophagus 18:326–338CrossRefPubMed
9.
Zurück zum Zitat Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T (2020) ESM-1 gene expression on outcomes in stage II/III gastric cancer patients who received adjuvant S-1 chemotherapy. Vivo 34:461–467CrossRef Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T (2020) ESM-1 gene expression on outcomes in stage II/III gastric cancer patients who received adjuvant S-1 chemotherapy. Vivo 34:461–467CrossRef
10.
Zurück zum Zitat Durston AJ, Timmermans JP, Hage WJ, Hendriks HF, de Vries NJ, Heideveld M, Nieuwkoop PD (1989) Retinoic acid causes an anteroposterior transformation in the developing central nervous system. Nature 340:140–144CrossRefPubMed Durston AJ, Timmermans JP, Hage WJ, Hendriks HF, de Vries NJ, Heideveld M, Nieuwkoop PD (1989) Retinoic acid causes an anteroposterior transformation in the developing central nervous system. Nature 340:140–144CrossRefPubMed
11.
Zurück zum Zitat Means A, Gudas LJ (1995) The roles of retinoids in vertebrate development. Annu Rev Biochem 64:210–233CrossRef Means A, Gudas LJ (1995) The roles of retinoids in vertebrate development. Annu Rev Biochem 64:210–233CrossRef
12.
Zurück zum Zitat Petkovich M, Brand NJ, Krust A, Chambon P (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444–450CrossRefPubMed Petkovich M, Brand NJ, Krust A, Chambon P (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444–450CrossRefPubMed
13.
Zurück zum Zitat Osanai M, Sawada N, Lee GH (2010) Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene 29:1135–1144CrossRefPubMed Osanai M, Sawada N, Lee GH (2010) Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene 29:1135–1144CrossRefPubMed
14.
Zurück zum Zitat Osanai M (2017) Cellular retinoic acid bioavailability in various pathologies and its therapeutic implication. Pathol Int 67:281–289CrossRefPubMed Osanai M (2017) Cellular retinoic acid bioavailability in various pathologies and its therapeutic implication. Pathol Int 67:281–289CrossRefPubMed
15.
Zurück zum Zitat Osanai M, Takasawa A, Takasawa K, Kyuno D, Ono Y, Magara K (2023) Retinoic acid metabolism in cancer: potential feasibility of retinoic acid metabolism blocking therapy. Med Mol Morphol 56:1–10CrossRefPubMed Osanai M, Takasawa A, Takasawa K, Kyuno D, Ono Y, Magara K (2023) Retinoic acid metabolism in cancer: potential feasibility of retinoic acid metabolism blocking therapy. Med Mol Morphol 56:1–10CrossRefPubMed
16.
Zurück zum Zitat Van heusden J, Wouters W, Ramaekers FC, Krekels MD, Dillen L, Borgers M, Smets G, (1998) The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br J Cancer 77:1229–1235CrossRefPubMed Van heusden J, Wouters W, Ramaekers FC, Krekels MD, Dillen L, Borgers M, Smets G, (1998) The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br J Cancer 77:1229–1235CrossRefPubMed
17.
Zurück zum Zitat Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovich M, van der Burg B, van der Saag PT (1998) Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Diff 9:629–637PubMed Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovich M, van der Burg B, van der Saag PT (1998) Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Diff 9:629–637PubMed
18.
Zurück zum Zitat Iaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ (2001) Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br J Cancer 85:630–635CrossRef Iaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ (2001) Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br J Cancer 85:630–635CrossRef
19.
Zurück zum Zitat Ozpolat B, Mehta K, Tari AM, Tari AM, Lopez-Berestein G (2002) All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 70:39–47CrossRefPubMed Ozpolat B, Mehta K, Tari AM, Tari AM, Lopez-Berestein G (2002) All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 70:39–47CrossRefPubMed
20.
Zurück zum Zitat Shelton DN, Sandoval IT, Eisinger A, Chidester S, Ratnayake A, Ireland CM, Jones DA (2006) Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res 66:7571–7577CrossRefPubMed Shelton DN, Sandoval IT, Eisinger A, Chidester S, Ratnayake A, Ireland CM, Jones DA (2006) Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res 66:7571–7577CrossRefPubMed
21.
Zurück zum Zitat WHO Classification of Tumours Editorial Board 2020 Female genital tumours. International Agency for Research on Cancer (WHO classification of tumours Lyon series, 5th ed.; vol.4) WHO Classification of Tumours Editorial Board 2020 Female genital tumours. International Agency for Research on Cancer (WHO classification of tumours Lyon series, 5th ed.; vol.4)
22.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458CrossRef
23.
Zurück zum Zitat Straight SW, Hinkle PM, Jewers RJ, McCance DJ (1993) The E5 oncoprotein of human papilloma virus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 67:4521–4532CrossRefPubMedPubMedCentral Straight SW, Hinkle PM, Jewers RJ, McCance DJ (1993) The E5 oncoprotein of human papilloma virus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 67:4521–4532CrossRefPubMedPubMedCentral
Metadaten
Titel
Elevated expression of endocan in the development of cervical squamous neoplasia of the uterus
verfasst von
Midori Sato
Ayano Inoue
Akira Takasawa
Kumi Takasawa
Daisuke Kyuno
Yusuke Ono
Kazufumi Magara
Makoto Osanai
Publikationsdatum
19.04.2023
Verlag
Springer Nature Singapore
Erschienen in
Medical Molecular Morphology / Ausgabe 3/2023
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-023-00353-0

Neu im Fachgebiet Pathologie

Pathologie der Milz

Nach einer Beschreibung der Milzanatomie und Darstellung der diagnostisch wichtigsten immunhistochemischen Färbungen zur Identifizierung der normalen Milzkompartimente werden am Beispiel eines nordafrikanischen Patienten mit rezentem …

Molekular definierte Nierenzellkarzinome 2025

Im Zuge der Überarbeitung der WHO-Klassifikation im Jahr 2022 konnten für mehrere Nierenzellkarzinome (NZK), die sich zuvor nicht eindeutig den bis dahin definierten Tumortypen zuordnen ließen, jedoch gemeinsame morphologische und molekulare …

Wichtige Änderungen in der WHO-Klassifikation der Hodentumoren 2022

In der 5. Auflage der „WHO-Klassifikation der Tumoren der ableitenden Harnwege und des männlichen Genitaltrakts“ sind bedeutende Anpassungen an den bisherigen Klassifikationen vorgenommen worden. Diese betreffen bei den Keimzelltumoren des Hodens …

DNA mixture deconvolution using fully continuous models EuroForMix and EFMrep

  • Open Access
  • Originalien

Mixture deconvolution is a powerful tool for inferring individual DNA profiles from DNA mixtures for subsequent transmission to a database or database queries. To carry out deconvolution, a mixed trace can be interpreted either manually by an …